CJC-1295: Durability Engineering in Its Purest Form

Abstract, in plain English

CJC-1295 is a laboratory-built copy of the first twenty-nine amino acids of the hormone that tells the pituitary gland to release growth hormone. The natural version is destroyed within minutes. This one was altered in four places so the body's cutting enzymes no longer recognise it, and then — in its long-acting form — given a chemical hook that binds permanently to albumin, the most abundant protein in blood. Riding on albumin, it lasts for days.

The numbers are unusually clear. In healthy adults, a single injection raised average growth hormone two- to ten-fold for six days or more and IGF-1 one-and-a-half to three-fold for nine to eleven days, with an estimated half-life of 5.8 to 8.1 days ^[9]. In a separate study, growth hormone remained pulsed in its normal rhythm rather than flattened ^[10].

It has never been approved for people anywhere. Its published human record consists of a small number of early pharmacology studies, and it is banned in sport.

Definition and provenance

CJC-1295 is a synthetic analogue of growth-hormone-releasing hormone, built on hGRF(1-29) — the first twenty-nine residues of human growth-hormone-releasing factor, the fragment that carries the receptor-activating activity of the full hormone. Four amino-acid substitutions are made to that scaffold: D-Ala at position 2, Gln at 8, Ala at 15 and Leu at 27. Together they stabilise the alpha-helix and block dipeptidylpeptidase-IV cleavage, deamidation and oxidation — the three routes by which the native fragment is normally lost.

The compound then splits into two forms that the literature and the marketplace routinely confuse. In the DAC form — Drug Affinity Complex — a C-terminal lysine carries a maleimidopropionyl linker that undergoes Michael addition with the free thiol on cysteine 34 of circulating serum albumin, forming a covalent peptide-albumin conjugate whose plasma persistence approaches albumin's own. In the no-DAC form, marketed as Modified GRF 1-29, the four substitutions remain but the albumin-binding handle does not, so the molecule is short-acting.

The original screening work makes the logic explicit. A series of hGRF(1-29) analogues bearing the maleimidopropionyl-lysine handle was tested; the lead candidate combined the four DPP-IV-protective substitutions with covalent albumin bioconjugation, produced a four-fold increase in growth-hormone area under the curve over two hours compared with unconjugated hGRF(1-29) in rats, remained detectable in plasma beyond seventy-two hours, and showed enhanced in vitro stability against dipeptidylpeptidase-IV ^[12].

Mechanism

CJC-1295 binds the growth-hormone-releasing hormone receptor on anterior-pituitary somatotrophs, activating Gs/cAMP/PKA signalling that drives the synthesis and pulsatile release of growth hormone. Circulating growth hormone in turn raises hepatic production of insulin-like growth factor 1, and it is IGF-1 — with its long serum residence — that carries most of the downstream anabolic signal.

The pharmacologically interesting question is what continuous receptor stimulation does to a system that normally operates in pulses. The answer, at least in the published human work, is less than might be expected: in healthy men aged twenty to forty, a single subcutaneous dose raised trough growth hormone roughly seven-and-a-half-fold, mean growth hormone by about 46 per cent and IGF-1 by about 45 per cent one week later, while the frequency and magnitude of pulsatile secretion were unaltered ^[10]. Pulsatility survives continuous stimulation.

The class context is set out in a 2024/2025 Nature Reviews Endocrinology synthesis of growth-hormone-releasing hormone and its analogues — the family that also contains sermorelin and tesamorelin — covering receptor signalling, the design rationale behind long-acting analogues, and their therapeutic and investigational landscapes ^[6].

The published record

The human pharmacology is the strongest part of the file. Single subcutaneous doses of 30 or 60 micrograms per kilogram in healthy adults produced dose-dependent two- to ten-fold increases in mean plasma growth hormone lasting six days or more, and one-and-a-half to three-fold increases in IGF-1 lasting nine to eleven days; after multiple doses IGF-1 remained above baseline for up to twenty-eight days, and the estimated half-life of the compound itself was 5.8 to 8.1 days ^[9]. A companion study in healthy men given a single 60 or 90 microgram-per-kilogram dose found trough growth hormone raised approximately seven-and-a-half-fold, mean growth hormone up about 46 per cent and IGF-1 up about 45 per cent one week after dosing, with pulsatile secretion unchanged ^[10].

A proteomic study in eleven healthy young adult men looked for a fingerprint of that axis activation and found one: apolipoprotein A1 and a transthyretin isoform decreased, a C-terminal albumin fragment and immunoglobulin and beta-haemoglobin species increased, and the immunoglobulin and albumin-fragment signal correlated linearly with IGF-1 — candidate biomarkers of growth-hormone-axis activation ^[8].

The animal work establishes that the long-acting design is sufficient rather than merely convenient. In GHRH-knockout mice, 2 micrograms of CJC-1295 given once every twenty-four hours fully normalised body weight and length, whereas dosing every forty-eight to seventy-two hours was progressively less effective; pituitary growth-hormone messenger RNA rose with treatment ^[11].

One further study belongs in the record for a different reason. CJC-1295 was structurally identified by high-resolution tandem mass spectrometry as the active ingredient of an unlabelled growth-hormone-releasing preparation seized in an anti-doping context ^[7] — a reminder that the compound's real-world circulation runs well ahead of its clinical file.

Reported effects and documented cautions

The material in this section is anecdotal, not clinical evidence: it is drawn from self-reported experience in research-use communities, tested by no controlled trial, and carries no doses.

Deeper and more restful sleep is by a clear margin the most commonly reported effect, and it is usually the first thing people say they notice. That report at least sits alongside known biology, since growth hormone is released chiefly during deep sleep. Faster recovery between hard training sessions and less lingering soreness form the second cluster, and gradual fat loss around the midsection over several weeks the third, generally described as showing up between weeks three and six and only alongside consistent diet and training. A leaner appearance and better muscle retention while dieting are frequently described. More daytime energy, sharper focus and firmer-feeling skin appear at lower frequency, and community members themselves tend to attribute the first two to better sleep rather than to any direct effect.

The adverse reports are led, unmistakably, by fluid retention: mild bloating, a heavier feeling, puffiness in the hands and face. Communities consistently note that this is more pronounced with the long-acting DAC form than with the short-acting no-DAC version, which is precisely the pattern the pharmacology predicts. Tingling or numbness in the hands and fingers, often compared to mild carpal tunnel, is attributed to the same fluid shift pressing on nerves at the wrist. Injection-site reactions are common. Flushing or a brief head rush shortly after injecting is reported more with the short-acting form. Fatigue, headache and increased appetite appear occasionally, with appetite reports concentrated among people combining the compound with ipamorelin. Higher blood sugar or reduced insulin sensitivity is reported less often but is flagged by community members themselves as a concern for anyone with existing glucose problems.

The documented cautions run parallel. It is not approved for human use anywhere, and the published human evidence is limited to a small number of early pharmacology studies ^[9][10] with no long-term trials in healthy adults. Sustained IGF-1 elevation carries a theoretical cancer concern: population epidemiology links higher circulating IGF-1 to a modestly increased risk of certain cancers, and the DAC form keeps IGF-1 elevated for days ^[9] — an association from population data, not proof of causation by this compound. Fluid retention and nerve compression follow mechanically from growth hormone's effect on renal sodium and water handling, which makes the community reports of puffiness and wrist tingling a mechanism-based expectation rather than a curiosity. Blood sugar and insulin sensitivity are a real concern because growth hormone is glucose-sparing, and prolonged axis stimulation can reduce insulin sensitivity. Immunogenicity was flagged by the FDA in 2024 briefing materials for the Pharmacy Compounding Advisory Committee, as part of the basis for not recommending CJC-1295 for the 503A compounding bulks list. The original long-acting development programme was discontinued, and a patient death during that era is frequently cited alongside the halted Phase 2 trial; the public record does not establish that CJC-1295 caused it, and it should be read as unresolved history rather than proof of harm. The DAC and no-DAC forms are routinely conflated, which matters for safety because only one of them sustains exposure for days. And it is prohibited at all times in sport under WADA Section S2, with well-established detection methods.

Its position in the coalition

CJC-1295 is the lead compound of this review because it isolates the variable. Its parent molecule, hGRF(1-29), is a well-characterised fragment with minutes of useful life. The analogue differs from it in four residues and one covalent bond, and that is the entire change — yet the published half-life moves to 5.8 to 8.1 days ^[9] and the biological signal persists for weeks ^[9].

What follows from that is instructive in both directions. The engineering delivered a compound whose human studies could be built around single doses and week-long sampling windows ^[9][10], which is why its human record, though small, is quantitatively precise where BPC-157's is not. It also delivered a compound whose most-reported downside is sustained rather than transient — fluid retention that persists for days rather than a flush that passes in minutes — because the same albumin tether that holds the peptide in circulation holds its pharmacology there too.

And it delivered a compound that never became a medicine. Durability is necessary for an approvable drug but nowhere near sufficient: the development programme was discontinued, the FDA declined to recommend the substance for compounding, and the molecule now circulates almost entirely outside the system that would have generated the trials ^[7]. Semaglutide, reviewed next, used the same two engineering moves — protease-blocking substitution and an albumin tether — and took them all the way through. The comparison between those two is the sharpest thing this review has to offer.